Ovarian Cancer

Modeling Agent

Ovarian Organoid ^{[1] [2]}

Drugs Approved

Chemotherapy Regimens

BEP/PEB

Bleomycin sulfate

Etoposide

Cisplatin

CARBOPLATIN-TAXOL

Carboplatin

Paclitaxel

GEMCITABINE-CISPLATIN

Gemcitabine Hydrochloride

Cisplatin

JEB

Carboplatin

Etoposide

Bleomycin sulfate

VAC

Vincristine

Actinomycin D

Cyclophosphamide

VeIP

Vinblastine sulfate

Ifosfamide

Cisplatin

Immune Checkpoint Inhibitors

PD-1

Pembrolizumab

Dostarlimab

Cemiplimab

Camrelizumab

Sintilimab

Nivolumab

Serplulimab

PD-L1

Atezolizumab

Durvalumab

Avelumab

Adebrelimab

Sugemalimab

CTLA-4

Nurulimab

Zalifrelimab

Quavonlimab

Ipilimumab

Tremelimumab

Anti-Angiogenesis ^[3]

VEGFR

Bevacizumab

Pazopanib

Cediranib

E7080

Regorafenib

FGFR

Sorafenib

Ponatinib

BIBF 1120

Angiotensin

Angiotensin II human Acetate

Angiotensin

Olmesartan

Endothelin

Zibotentan

BQ-123

Ambrisentan

IL-6

Tocilizumab

Sarilumab

Methylprednisolone

IL-8

SB 225002

Aprepitant

PDGFR

Crenolanib

Ripretinib

DNA Repair-Related ^[3]

PARP

AZD2281

Veliparib

Rucaparib

Niraparib

DNA Alkylator

Melphalan

Trabectedin

Oxaliplatin

Carboplatin

Cyclophosphamide Monohydrate

RAD51

Amuvatinib

RI-1

RS-1

BRCA1

Bractoppin

ATM

AZD0156

AZD1390

AZ32

KU-60019

KU-55933

Platinum-Related ^[3]

Platinum-Sensitive

Carboplatin

Paclitaxel

Gemcitabine Hydrochloride

Bevacizumab

Cediranib

Niraparib

Doxorubicin (Adriamycin) Hydrochloride

Trabectedin

AZD2281

Platinum-Resistant

Paclitaxel

Bevacizumab

Doxorubicin (Adriamycin) Hydrochloride

Topotecan HCl

Cediranib

Targeted Therapy (A) ^{[3] [4]}

TP53

Pifithrin-α (PFTα) Hhydrobromide

Pifithrin-μ

PRIMA-1

HER2

Trastuzumab

Pertuzumab

Margetuximab

Trastuzumab deruxtecan

Trastuzumab Emtansine（T-DM1）

Disitamab vedotin

Trastuzumab MMAE

PI3K

LY294002

Wortmannin

Alpelisib

Copanlisib

CAL-101

mTOR

RAD001

Temsirolimus

OSI-027

MYC

10058-F4

10074-G5

KRAS G12D

MRTX1133

KRpep-2d

BI-2865

KRAS G12C

Adagrasib

AMG 510

ARS-1620

Targeted Therapy (B) ^[3]

PTEN

VO-Ohpic trihydrate

bpV

MDM2

Nutlin-3

Nutlin-3a

Triptolide

(-)-Parthenolide

CA-125/MUC16

Oregovomab

Abagovomab

Sofituzumab

Sofituzumab vedotin

Notch

Crenigacestat

Limantrafin

BRAF

Sorafenib

PLX4032

Dabrafenib

CDK2

SNS-032

CVT-313

Milciclib

HSP90

Ganetespib

Apoptozole

NMS-E973

Targeted Therapy (C) ^[3]

ERBB3/HER3

Patritumab

Seribantumab

Lumretuzumab

Patritumab deruxtecan

FRalpha

Mirvetuximab

Farletuzumab

Mirvetuximab-MMAE

FOXM1

RCM-1

FDI-6

BRD4

ABBV-744

dBET6

AURKA

Alisertib

Tozasertib

MLN8054

SMARCA4

PFI-3

ACBI1

AU-15330

KLF5

ML264

SR18662

mAb & ADC

HER2

Trastuzumab

Pertuzumab

Margetuximab

Trastuzumab deruxtecan

Trastuzumab Emtansine（T-DM1）

Disitamab vedotin

Trastuzumab MMAE

CA-125/MUC16

Oregovomab

Abagovomab

Sofituzumab

Sofituzumab vedotin

ERBB3/HER3

Patritumab

Seribantumab

Barecetamab

Lumretuzumab

Patritumab deruxtecan

FRalpha

Mirvetuximab

Farletuzumab

Mirvetuximab-MMAE

Compound Library